Phathom Pharmaceuticals, Inc. (PHAT) Profit Margins
Over the twelve months to 2026-06-30, Phathom Pharmaceuticals, Inc. (PHAT) had gross margin 82.9%, operating margin -17.0%, net margin -41.3%, free cash flow margin -15.4%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PHATPhathom Pharmaceuticals, Inc.Follow PHAT — free
—
Price chart with a free account
- Market cap
- 464.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Gross margin | 75.5% | 85.6% | 87.1% | 82.9% | |
| Operating margin | -24532.6% | -502.2% | -91.4% | -17.0% | |
| Net margin | -29558.9% | -605.1% | -126.3% | -41.3% | |
| FCF margin | -20412.6% | -483.1% | -95.4% | -15.4% |
USD millions · SEC XBRL
Phathom Pharmaceuticals, Inc. — questions
- What is Phathom Pharmaceuticals, Inc.'s gross margin?
- 82.9% over the twelve months to 2026-06-30.
- What is Phathom Pharmaceuticals, Inc.'s operating margin?
- -17.0% over the twelve months to 2026-06-30.
- What is Phathom Pharmaceuticals, Inc.'s net profit margin?
- -41.3% over the twelve months to 2026-06-30.
Every figure on this page comes from Phathom Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.